HC Wainwright Reiterates “Buy” Rating for Outlook Therapeutics (NASDAQ:OTLK)

HC Wainwright reissued their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock.

OTLK has been the topic of several other reports. BTIG Research lowered their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, November 29th. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Outlook Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $28.07.

Outlook Therapeutics Stock Performance

NASDAQ:OTLK opened at $2.23 on Friday. The company has a market capitalization of $55.55 million, a price-to-earnings ratio of -0.25 and a beta of 0.53. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85. The stock has a 50-day simple moving average of $2.70 and a 200 day simple moving average of $5.33.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings results on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.06. On average, equities research analysts forecast that Outlook Therapeutics will post -2.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Outlook Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of OTLK. Christensen King & Associates Investment Services Inc. acquired a new stake in shares of Outlook Therapeutics in the 3rd quarter valued at $55,000. AQR Capital Management LLC acquired a new stake in shares of Outlook Therapeutics in the 2nd quarter valued at $75,000. Barclays PLC lifted its stake in shares of Outlook Therapeutics by 677.4% in the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Outlook Therapeutics in the 3rd quarter valued at $199,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Outlook Therapeutics in the 2nd quarter valued at $232,000. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.